MDA Space Ltd. (MDA)vsVersamet Royalties Corporation Common Stock (VMET)
MDA
MDA Space Ltd.
$34.61
+1.05%
NONE · Cap: $4.43B
VMET
Versamet Royalties Corporation Common Stock
$12.18
+3.75%
NONE · Cap: $1.29B
Smart Verdict
WallStSmart Research — data-driven comparison
MDA Space Ltd. generates 5938% more annual revenue ($2.10B vs $34.76M). VMET leads profitability with a 58.5% profit margin vs 2.2%. MDA trades at a lower P/E of 51.9x. VMET earns a higher WallStSmart Score of 45/100 (D+).
MDA
Avoid33
out of 100
Grade: F
VMET
Hold45
out of 100
Grade: D+
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
No standout strengths identified
Keeps 59 of every $100 in revenue as profit
Strong operational efficiency at 135.6%
Revenue surging 465.2% year-over-year
Areas to Watch
0.2% revenue growth
1.4% earnings growth
ROE of 0.0% — below average capital efficiency
2.2% margin — thin
0.0% earnings growth
Smaller company, higher risk/reward
Premium valuation, high expectations priced in
Comparative Analysis Report
WallStSmart ResearchBull Case : MDA
MDA has a balanced fundamental profile.
Bull Case : VMET
The strongest argument for VMET centers on Profit Margin, Operating Margin, Revenue Growth. Profitability is solid with margins at 58.5% and operating margin at 135.6%. Revenue growth of 465.2% demonstrates continued momentum.
Bear Case : MDA
The primary concerns for MDA are Revenue Growth, EPS Growth, Return on Equity. A P/E of 51.9x leaves little room for execution misses. Thin 2.2% margins leave little buffer for downturns.
Bear Case : VMET
The primary concerns for VMET are EPS Growth, Market Cap, P/E Ratio. A P/E of 56.6x leaves little room for execution misses.
Key Dynamics to Monitor
MDA profiles as a value stock while VMET is a growth play — different risk/reward profiles.
VMET is growing revenue faster at 465.2% — sustainability is the question.
Monitor NONE industry trends, competitive dynamics, and regulatory changes.
Bottom Line
VMET scores higher overall (45/100 vs 33/100), backed by strong 58.5% margins and 465.2% revenue growth. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Versamet Royalties Corporation Common Stock
NONE · NONE · USA
Viamet Pharmaceuticals Corp (VMET) is a biopharmaceutical company focused on developing novel therapeutics for serious and life-threatening diseases, particularly through its innovative drug development platform that leverages its proprietary metalloenzyme-based technology. The company aims to address unmet medical needs in areas such as fungal infections and oncology, positioning itself at the forefront of therapeutic innovation. Viamet's strategic partnerships and strong intellectual property portfolio underscore its commitment to advancing its pipeline while maximizing shareholder value. As it progresses through clinical development phases, VMET stands to play a significant role in transforming treatment paradigms within its targeted therapeutic areas.
Compare with Other NONE Stocks
Want to dig deeper into these stocks?